A new drug, 'MariTide,' developed by Amgen, has shown significant potential in treating obesity, with trial participants losing up to 16% body weight annually.

Oppenheimer & Co. Inc. trimmed its stake in Amgen Inc. by 1.2% in Q1, selling 1,335 shares, bringing its holding to 109,833 ...

Amgen (AMGN) closed the most recent trading day at $280.35, moving +1.03% from the previous trading session. On the other hand, the Dow registered a loss of 0.25%, and the technology-centric Nasdaq ...

Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Shares of Amgen Inc. AMGN rallied 1.03% to $280.35 Wednesday, on what proved to be an all-around mixed trading session for ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Guselkumab, whether administered every 4 or 8 weeks, demonstrates “significant inhibition” of structural damage in patients ...

Cantor Fitzgerald reaffirmed a neutral rating on Amgen, setting a $305 price target for the medical research firm. Despite ...

Retired pro football hall-of-famer Barry Sanders revealed he had a heart attack in 2024. But now he working to help other ...

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about ...

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...